Abstract
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna’s mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log 10 reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log 10 reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
【초록키워드】 SARS-CoV-2, Vaccine, coronavirus, B.1.351, mRNA-1273, neutralization, variant, variants of concern, B.1.617.2, severe acute respiratory syndrome Coronavirus, immunization, airway, RNA, Replication, Viral, mRNA, nasal swab, respiratory, Critical, Antibody titers, Antibody neutralization, single dose, Moderna, Neutralizing antibody titer, Bronchoalveolar lavage, dose, reduction, mRNA-1273 vaccine, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, serum dilution, These data, live SARS-CoV-2, nasal swabs, inhibitory, two-dose regimen, groups, reduction in, neutralizing response, undetectable, 【제목키워드】 SARS-CoV-2, Infection, PROTECT,